Curative Effect Evaluation of Shexiang Baoxin Pill on Coronary Artery Disease Not Amenable to Revascularization

Coronary Artery Disease(CAD) Clinical Trial

Official title: Study of Curative Effect Evaluation of Shexiang Baoxin Pill on Coronary Artery Disease Not Amenable to Revascularization on the Basis of Western Medicine Therapy

Status Not yet recruiting

Clinical Trial Summary

The purpose of this study is to determine whether Shexiang Baoxin Pill is effective in the treatment of coronary artery disease not amenable to revascularization on the basis of western medicine therapy.

Clinical Trial Description

The western medicine treatment for CAD not amenable to revascularization is limited. Shexiang Baoxin Pill, a kind of Chinese patent medicine has been used for treating coronary artery disease in clinical practice in China for many years.

Shexiang baoxin pill(SBP) is applicable to "Qi deficiency and blood stasis syndrome" in traditional Chinese medicine. Recent experimental research has indicated that SBP can improve myocardial ischemia and promote therapeutic angiogenesis. ;

Related Conditions & MeSH terms

• Coronary Artery Disease
• Coronary Artery Disease(CAD)
• Coronary Disease
• Myocardial Ischemia

• NCT number: NCT03072121
• Study type: Interventional
• Source: Guang'anmen Hospital of China Academy of Chinese Medical Sciences
• Contact: Jun Li, MD
• Phone: +86 13051458913
• Email: 13051458913@163.com
• Status: Not yet recruiting
• Phase: Phase 4
• Start date: June 2017
• Completion date: February 2019